A ctDNA directed, multi center phase II study of molecular response adaptive immuno-chemotherapy in patients with non small cell lung cancer: Analysis of Stage 1 of CCTG BR.36

Valsamo Anagnostou (1,2), Cheryl Ho (3) , Garth Nicholas (4) , Rosalyn Anne Juergens (5) , Adrian Sacher (6) , Andrea Fung (7) , Paul Wheatley Price (4) , Scott A. Laurie (4) , Benjamin Levy (1) , Julie Brahmer (1,2), Archana Balan (1) , Noushin Niknafs (1) , Egor Avrutin (8) , Liting Zhu (8) , Mark Sausen (9) , Penelope Bradbury (6), Jill O'Donnell Tormey (10) , Pierre Olivier Gaudreau (8) , Keyue Ding (8) and Janet Dancey (8)

1The Sidney Kimmel Comprehensive Cancer Center, JHSM, Baltimore, MD, USA, 2 The Bloomberg Kimmel Institute for Cancer Immunotherapy, JHSM, Baltimore, MD, USA, 3 BC Cancer Vancouver Cancer Centre, Vancouver, British Columbia, Canada, 4 Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5 Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada, 6 University Health Network Princess Margaret Cancer Centre, Toronto, Ontario, Canada, 7 Kingston Health Sciences Centre, Kingston, Ontario, Canada, 8 Canadian Cancer Trials Group, Queen’s University, Kingston Ontario, Canada, 9 Personal Genome Diagnostics ( Labcorp ), Baltimore, MD, USA, 10 Cancer Research Institute, New York, NY, USA